Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders

ObjectivesThe primary objective of this project was to explore the challenges related to the implementation of patient-reported outcome measures (PROMs) in myeloma, lymphoma and leukaemia patients undergoing chimeric antigen receptor T-cell (CAR-T) and T Cell engager bispecific antibody (BsAbs) ther...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Eilidh M Duncan, Jhulia Salviano, Charalampia Kyriakou, Samantha Nier, Simone Oerlemans, Sam Salek, Kate Morgan, Katie Joyner
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2026-05-01
coleção:	Frontiers in Hematology
Assuntos:	bispecific antibodies chimeric antigen receptor T-cell therapy (CAR-T) clinical trials haematological malignancies patient-reported outcome measures (PROM) patient-reported outcomes (PRO)
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/frhem.2026.1800304/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!